Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 23;9(5):ofac090.
doi: 10.1093/ofid/ofac090. eCollection 2022 May.

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties

Affiliations

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties

Randall K Hoover et al. Open Forum Infect Dis. .

Abstract

Background: There is a need for improved antibiotic formulations for the treatment of acute bacterial skin and soft structure infection (ABSSSI), especially with the rise of antimicrobial resistance among Gram-positive bacteria. A new formulation of oritavancin was developed to reduce intravenous infusion volume (from 1000 mL to 250 mL), shorten infusion time (from 3 hours to 1 hour), and provide pharmacies with flexibility in oritavancin preparation (from 5% dextrose in sterile water to either normal saline or 5% dextrose in sterile water) compared with the current formulation.

Methods: A total of 102 adult patients with a diagnosis of ABSSSI suspected or confirmed to be caused by a Gram-positive pathogen were randomized 1:1 to receive either the new formulation of oritavancin or the current formulation. After a single 1200-mg intravenous infusion of oritavancin, the relative area-under-the-curve exposure of the new formulation and current formulation groups were compared. Safety and tolerability of the new formulation were assessed for treatment-emergent adverse events, serious adverse events, and changes to laboratory parameters.

Results: The area under the curve for 0 hour to 72 hours postdose was very similar in the new formulation group compared with the current formulation group. No differences in treatment-emergent adverse events were observed between the current and new formulation groups, and all treatment-emergent adverse events were consistent with the known safety profile of the current formulation.

Conclusions: The new formulation of oritavancin with reduced volume and duration of intravenous infusion demonstrates a safety profile and pharmacokinetics similar to that of the original formulation.

Keywords: ABSSSI; oritavancin; pharmacokinetics; skin infections.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Oritavancin plasma concentration (µg/mL) versus time (pharmacokinetic population) after a single 1200-mg intravenous infusion. Scaling: A, linear; B, semi-logarithmic. Symbols represent the geometric mean at each time point with +/- geometric standard deviation error bars.

References

    1. Lipsky BA, Moran GJ, Napolitano LM, et al. . Prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis 2012; 12:227. - PMC - PubMed
    1. Garau J, Ostermann H, Medina J, et al. . Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19:E377–85. - PubMed
    1. Klein EY, Sun L, Smith DL, Laxminarayan R.. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am J Epidemiol 2013; 177:666–74. - PubMed
    1. Diekema J, Pfaller MA, Shortridge D, et al. . Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open Forum Infect Dis 2019; 6:S47–53. - PMC - PubMed
    1. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28:603–61. - PMC - PubMed